Every 8-K that PROTAGENIC THERAPUTCS WTS (PTIXW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PTIXW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTIXW filings page.
Protagenic Therapeutics, Inc. has appointed William (Bill) Nichols, Jr., age 51, as President effective February 3, 2026. He brings senior commercial leadership experience from bluebird bio, Dova Pharmaceuticals (now Sobi), and Bristol-Myers Squibb, all in the biotechnology and biopharmaceutical space.
Under his employment agreement, Mr. Nichols will receive a base salary of $350,000 and is eligible for an annual target bonus equal to 40% of his base salary. The agreement also provides for a stock option grant equal to approximately 1.0% of the company’s fully diluted share count. The company states there are no special arrangements or family relationships related to his selection and no related-party transactions requiring disclosure.
Protagenic Therapeutics, Inc. filed an amended current report to update a consent exhibit connected to its earlier acquisition of Phytanix Bio. The company previously completed a share exchange in which it acquired 100% of the common and preferred shares of Phytanix, bringing that Nevada corporation under its control.
This latest amendment revises Item 9.01 solely to update Exhibit 23.1, the consent of GreenGrowth CPAs Inc. No other parts of the prior amended report, including the historical and unaudited pro forma financial statements for the combination with Phytanix, are changed.
Protagenic Therapeutics, Inc. (PTIXW) amended a material event report to disclose near-term clinical milestones for its oncology candidate PT00114 and filing of transaction-related pro forma financials. The company expects to complete the multiple-dose portion of the Phase I study for PT00114 and make those results publicly available in Q2 FY2026 (quarter ending September 30, 2025). It also anticipates initiating a Phase IIa study for PT00114 in Q4 FY2026 (quarter ending March 31, 2026). The unaudited pro forma combined statement of operations for the year ended March 31, 2025, related to the described transaction, is filed as Exhibit 99.2 to this Form 8-K/A and is incorporated by reference.
Protagenic Therapeutics, Inc. reports that Nasdaq has notified the company it is not in compliance with Listing Rule 5250(c)(1) because its Form 10-Q for the quarter ended June 30, 2025 has not yet been filed. The notice does not immediately affect trading of the PTIX common stock or PTIXW warrants on the Nasdaq Capital Market, and the company plans to submit a compliance plan within 60 days, with Nasdaq able to grant up to 180 days from the 10-Q due date.
The company also replaced MaloneBailey, LLP with Green Growth CPAs as its independent registered public accounting firm, with no reported disagreements or other reportable events, although MaloneBailey’s 2024 report included a going concern explanatory paragraph. In addition, Protagenic announced completion of first-dose injections for all subjects in the multiple-dose part of its Phase I trial of PT00114, expects topline safety data by the end of September 2025, and is planning Phase 2 efficacy studies for the first quarter of 2026.
Protagenic Therapeutics approved a focused restructuring to transition to a virtual operating model and concentrate capital on its lead clinical asset, PT00114. The Board expects this plan to reduce annualized operating expenses by approximately $8 million while pausing preclinical programs (PHYX-001 through PHYX-005) to pursue partnerships or out-licensing and conserve cash for the Phase 2 trial. The Company currently expects the Phase 2 for PT00114 to complete in approximately 9 to 12 months, subject to enrollment and customary factors.
The plan eliminates certain executive roles by terminating the employment of the CEO and COO, who remain on the Board, and reduces headcount primarily tied to preclinical, regulatory, and IP functions. The Company expects one-time charges related to the restructuring but cannot yet estimate amounts or timing. The Company also changed its fiscal year-end to March 31.